Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical Inc. (Nasdaq: COLL) specializes in developing abuse-deterrent medications for chronic pain and neuropsychiatric conditions through its proprietary DETERx® technology. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, product developments, and strategic initiatives shaping the company's trajectory in specialty pharmaceuticals.
Access comprehensive coverage of COLL's latest press releases, including advancements in pain management solutions like Xtampza ER® and Nucynta®, as well as its expansion into ADHD treatment with Jornay PM®. The page aggregates essential updates on financial performance, partnership announcements, and intellectual property developments critical for assessing the company's market position.
Bookmark this resource for structured access to Collegium's most significant announcements, from clinical trial results to manufacturing updates. Our curated news feed ensures you stay informed about COLL's efforts to address opioid misuse while delivering innovative therapeutic solutions across multiple medical disciplines.
Collegium Pharmaceutical (Nasdaq: COLL) reported strong Q2 2025 financial results, achieving record quarterly revenue of $188.0 million, up 29% year-over-year. The company's ADHD medication Jornay PM generated record revenue of $32.6 million with 23% prescription growth, while the pain portfolio contributed $155.4 million, up 7% year-over-year.
The company raised its 2025 guidance, now expecting full-year revenue between $745-760 million and adjusted EBITDA of $440-455 million. Q2 highlights include adjusted EBITDA of $105.1 million and cash position of $222.2 million. The Board authorized a new $150 million share repurchase program through 2026, following completion of a $25 million accelerated share repurchase.
Collegium Pharmaceutical (Nasdaq: COLL) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, before market opening. The company will host a conference call and webcast at 8:00 a.m. ET following the release.
Investors can access the conference call via (877) 407-8037 (U.S.) or (201) 689-8037 (International). An audio webcast will be available on the company's website investor section and will remain accessible for replay approximately two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) has announced a new $150 million share repurchase program effective through December 31, 2026. This program replaces their previous $150 million authorization from January 2024, which expired with $65 million unused.
The company has demonstrated strong commitment to shareholder value, having returned $222 million to shareholders through repurchase programs since 2021. This includes a $25 million accelerated share repurchase initiated in May 2025. As of March 31, 2025, Collegium had approximately 32.1 million shares outstanding.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in two upcoming investor conferences:
1. The Mizuho Neuro & Ophthalmology Summit 2025, where management will participate in a panel presentation on Wednesday, May 21, 2025, at 11:25 a.m. ET
2. The Jefferies Global Healthcare Conference, featuring a presentation on Thursday, June 5, 2025, at 1:25 p.m. ET. This presentation will be webcast live and accessible through the company's investor relations website, with a replay available for 90 days following the event.
Collegium Pharmaceutical (NASDAQ: COLL) has announced a $25 million Accelerated Share Repurchase (ASR) agreement with Jefferies LLC. This ASR is part of a larger $150 million share repurchase program authorized in January 2024, with $65 million remaining after this transaction. The company will receive an initial delivery of 692,281 shares at $28.89 per share, representing approximately 80% of expected total shares under the ASR.
The company reported strong Q1 2025 performance with 23% year-over-year revenue growth, driven by its pain portfolio and ADHD medicine Jornay PM®. The final settlement of the ASR is expected by Q3 2025, with the final share count based on volume-weighted average prices. As of March 31, 2025, Collegium had approximately 32.1 million shares outstanding.
Collegium Pharmaceutical (Nasdaq: COLL) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results.
Investors can access the conference call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers. An audio webcast will be available through the Investors section of Collegium's website and will remain accessible for replay approximately two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in the 24th Annual Needham Healthcare Conference, which will be held virtually from April 7-10, 2025. The company's management will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 9:30 a.m. ET.
The fireside discussion will be accessible through a live webcast on the Investors section of Collegium's website. Interested parties can view the presentation at https://ir.collegiumpharma.com, and a replay will remain available on the company's website for 90 days following the event.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its upcoming presentation of four posters featuring real-world patient data from its pain management portfolio at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting in Austin, TX, from April 3-6, 2025.
A notable highlight is their poster on 'Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids,' which has been selected as a top abstract and will be published in AAPM's Pain Medicine Journal. The presentations will focus on their key products, including BELBUCA® (buprenorphine buccal film) and Xtampza® ER (oxycodone), both prescribed for severe pain management requiring daily, long-term opioid treatment.
Dr. Thomas Smith, Chief Medical Officer, emphasized the significance of presenting meaningful real-world data for healthcare professionals treating pain patients, reinforcing Collegium's position as a leader in responsible pain management.
Collegium Pharmaceutical (COLL) announced significant changes to its Board of Directors and executive leadership team. Founder and Chairman Michael Heffernan and Board Member Gwen A. Melincoff will retire at the Annual General Meeting on May 15, 2025. Gino Santini, current Lead Independent Director, will become Chairman, while Dr. Carlos Paya will be nominated to the Board.
The company also appointed three new executive leaders: David Dieter as Executive VP and General Counsel, Jane Gonnerman as Executive VP of Strategy and Corporate Development, and Dean J. Patras as Chief People Officer. These appointments come as Collegium enters a new growth phase focused on accelerating momentum for Jornay PM, maximizing its pain portfolio, and strategic capital deployment.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
